Marianne Ellen Pavel

Medizinische Fakultät Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology Professur für Endokrinologie

High rate of Ki-67 increase in entero-pancreatic NET relapses after surgery with curative intent (2022) Merola E, Perren A, Rinke A, Zerbi A, Mcnamara MG, Arsenic R, Fazio N, et al. Journal article Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time? (2022) Hope TA, Pavel ME, Bergsland EK Journal article, Review article DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms (2022) Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, et al. Journal article, Review article Immuntherapie bei neuroendokrinen Tumoren: Zeitpunkt und Zielgruppe (2022) Auernhammer CJ, Pavel ME Journal article ASO Visual Abstract: Radical Resection in Enteropancreatic Neuroendocrine Tumors-Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence (2022) Merola E, Pascher A, Rinke A, Bartsch DK, Zerbi A, Nappo G, Carnaghi C, et al. Journal article, Editorial Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT (2022) Zwirtz K, Hardt J, Acker G, Baur ADJ, Pavel ME, Huang K, Brenner W, Prasad V Journal article Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence (2022) Merola E, Pascher A, Rinke A, Bartsch DK, Zerbi A, Nappo G, Carnaghi C, et al. Journal article Neuroendocrine Tumor Treatments and Follow-up Disease Management: Comparative Perspective (US and Canada vs Global) (2022) Kolarova T, Hollander R, Mcdonnell M, Bouvier C, Pavel ME, Singh H, Howe J, et al. Conference contribution [Lu-177]Lu-DOTA-TATE as First-line Therapy for Patients With Grade 2 and 3 Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): The NETTER-2 Study (2022) Singh S, Pavel ME, Kunz PL, De Herder W, Herrmann K, D'Amelio AM, Santoro P, et al. Conference contribution Impact of a reduced dosing interval of lanreotide autogel (LAN) on tumor growth rate (TGR) in patients with progressive neuroendocrine tumors (NETs) in the prospective, single-arm, phase 2 CLARINET FORTE trial (2022) Dromain C, Cwikla JB, Lombard-Bohas C, Borbath , Shah T, Pape UF, Capdevila J, et al. Conference contribution